MR Measures of Small Bowel Wall T2 Are Associated With Increased Permeability.
Crohn's disease
diagnostic imaging
liver cirrhosis
magnetic resonance imaging
permeability
Journal
Journal of magnetic resonance imaging : JMRI
ISSN: 1522-2586
Titre abrégé: J Magn Reson Imaging
Pays: United States
ID NLM: 9105850
Informations de publication
Date de publication:
05 2021
05 2021
Historique:
revised:
24
11
2020
received:
09
10
2020
accepted:
24
11
2020
pubmed:
18
12
2020
medline:
20
5
2021
entrez:
17
12
2020
Statut:
ppublish
Résumé
Increased small bowel permeability leads to bacterial translocation, associated with significant morbidity and mortality. Biomarkers are needed to evaluate these changes in vivo, stratify an individual's risk, and evaluate the efficacy of interventions. MRI is an established biomarker of small bowel inflammation. To characterize changes in the small bowel with quantitative MRI measures associated with increased permeability induced by indomethacin. Prospective single-center, double-blind, two-way crossover provocation study. A provocation cohort (22 healthy volunteers) and intrasubject reproducibility cohort (8 healthy volunteers). 2D balanced turbo field echo sequences to measure small bowel wall thickness, T Participants were randomized to receive indomethacin or placebo prior to assessment. After a minimum 2-week washout, measures were repeated with the alternative allocation. MR measures (wall thickness, T Normality was tested (Shapiro-Wilk's test). Paired testing (Student's t-test or Wilcoxon) determined the significance of paired differences with indomethacin provocation. Pearson's correlation coefficient compared significant measures with indomethacin provocation to LMR. Intrasubject (intraclass correlation) and interrater variability (Bland-Altman) were assessed. Indomethacin provocation induced a significant increase in LMR compared to placebo (P < 0.05) and a significant increase in small bowel T MR measures of small bowel wall T 1 TECHNICAL EFFICACY STAGE: 2.
Sections du résumé
BACKGROUND
Increased small bowel permeability leads to bacterial translocation, associated with significant morbidity and mortality. Biomarkers are needed to evaluate these changes in vivo, stratify an individual's risk, and evaluate the efficacy of interventions. MRI is an established biomarker of small bowel inflammation.
PURPOSE
To characterize changes in the small bowel with quantitative MRI measures associated with increased permeability induced by indomethacin.
STUDY TYPE
Prospective single-center, double-blind, two-way crossover provocation study.
SUBJECTS
A provocation cohort (22 healthy volunteers) and intrasubject reproducibility cohort (8 healthy volunteers).
FIELD STRENGTH/SEQUENCE
2D balanced turbo field echo sequences to measure small bowel wall thickness, T
ASSESSMENT
Participants were randomized to receive indomethacin or placebo prior to assessment. After a minimum 2-week washout, measures were repeated with the alternative allocation. MR measures (wall thickness, T
STATISTICAL TESTS
Normality was tested (Shapiro-Wilk's test). Paired testing (Student's t-test or Wilcoxon) determined the significance of paired differences with indomethacin provocation. Pearson's correlation coefficient compared significant measures with indomethacin provocation to LMR. Intrasubject (intraclass correlation) and interrater variability (Bland-Altman) were assessed.
RESULTS
Indomethacin provocation induced a significant increase in LMR compared to placebo (P < 0.05) and a significant increase in small bowel T
DATA CONCLUSION
MR measures of small bowel wall T
LEVEL OF EVIDENCE
1 TECHNICAL EFFICACY STAGE: 2.
Types de publication
Journal Article
Randomized Controlled Trial
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
1422-1431Subventions
Organisme : Medical Research Council
ID : G1001119
Pays : United Kingdom
Informations de copyright
© 2020 International Society for Magnetic Resonance in Medicine.
Références
DeMeo MT, Mutlu EA, Keshavarzian A, Tobin MC. Intestinal permeation and gastrointestinal disease. J Clin Gastroenterol 2002;34(4):385-396.
Bischoff SC, Barbara G, Buurman W, et al. Intestinal permeability - A new target for disease prevention and therapy. BMC Gastroenterol 2014;14:189.
Camilleri M. Leaky gut: Mechanisms, measurement and clinical implications in humans. Gut 2019;68(8):1516-1526.
Thalheimer U, De Iorio F, Capra F, et al. Altered intestinal function precedes the appearance of bacterial DNA in serum and ascites in patients with cirrhosis: A pilot study. Eur J Gastroenterol Hepatol 2010;22(10):1228-1234.
Berg RD, Garlington AW. Translocation of certain indigenous bacteria from the gastrointestinal tract to the mesenteric lymph nodes and other organs in a gnotobiotic mouse model. Infect Immun 1979;23(2):403-411.
Koh IH, Guatelli R, Montero EF, et al. Where is the site of bacterial translocation-Small or large bowel? Transplant Proc 1996;28(5):2661.
MacFie J, O'Boyle C, Mitchell CJ, Buckley PM, Johnstone D, Sudworth P. Gut origin of sepsis: A prospective study investigating associations between bacterial translocation, gastric microflora, and septic morbidity. Gut 1999;45(2):223-228.
Cirera I, Bauer TM, Navasa M, et al. Bacterial translocation of enteric organisms in patients with cirrhosis. J Hepatol 2001;34(1):32-37.
Albillos A, de la Hera A, González M, et al. Increased lipopolysaccharide binding protein in cirrhotic patients with marked immune and hemodynamic derangement. Hepatology 2003;37(1):208-217.
Goulis J, Armonis A, Patch D, Sabin C, Greenslade L, Burroughs AK. Bacterial infection is independently associated with failure to control bleeding in cirrhotic patients with gastrointestinal hemorrhage. Hepatology 1998;27(5):1207-1212.
Senzolo M, Fries W, Buda A, et al. Oral propranolol decreases intestinal permeability in patients with cirrhosis: Another protective mechanism against bleeding? Am J Gastroenterol 2009;104(12):3115-3116.
Peyrin-Biroulet L, Gonzalez F, Dubuquoy L, et al. Mesenteric fat as a source of C reactive protein and as a target for bacterial translocation in Crohn's disease. Gut 2012;61(1):78-85.
Turpin W, Lee SH, Raygoza Garay JA, et al. Increased intestinal permeability is associated with later development of Crohn's disease. Gastroenterology 2020.10; S0016-5085(20):35021-35026.
Suenaert P, Bulteel V, Lemmens L, et al. Anti-tumor necrosis factor treatment restores the gut barrier in Crohn's disease. Am J Gastroenterol 2002;97(8):2000-2004.
Ciccia F, Guggino G, Rizzo A, et al. Dysbiosis and zonulin upregulation alter gut epithelial and vascular barriers in patients with ankylosing spondylitis. Ann Rheum Dis 2017;76(6):1123-1132.
Fasano A. All disease begins in the (leaky) gut: Role of zonulin-mediated gut permeability in the pathogenesis of some chronic inflammatory diseases. F1000Res 2020;69:1-13.
Rasmussen DN, Karstensen JG, Riis LB, Brynskov J, Vilmann P. Confocal laser endomicroscopy in inflammatory bowel disease-A systematic review. J Crohns Colitis 2015;9(12):1152-1159.
Bjarnason I, MacPherson A, Hollander D. Intestinal permeability: An overview. Gastroenterology 1995;108(5):1566-1581.
Smecuol E, Bai JC, Sugai E, et al. Acute gastrointestinal permeability responses to different non-steroidal anti-inflammatory drugs. Gut 2001;49(5):650-655.
Kelly CP, Green PH, Murray JA, et al. Larazotide acetate in patients with coeliac disease undergoing a gluten challenge: A randomized placebo-controlled study. Aliment Pharmacol Ther 2013;37(2):252-262.
Smith HE, Ryan KN, Stephenson KB, et al. Multiple micronutrient supplementation transiently ameliorates environmental enteropathy in Malawian children aged 12-35 months in a randomized controlled clinical trial. J Nutr 2014;144(12):2059-2065.
Vanuytsel T, Van Wanrooy S, Vanheel H, et al. Psychological stress and corticotropin-releasing hormone increase intestinal permeability in humans by a mast cell-dependent mechanism. Gut 2014;63(8):1293-1299.
Takeuchi K, Miyazawa T, Tanaka A, Kato S, Kunikata T. Pathogenic importance of intestinal hypermotility in NSAID-induced small intestinal damage in rats. Digestion 2002;66(1):30-41.
Tanaka A, Matsumoto M, Hayashi Y, Takeuchi K. Functional mechanism underlying cyclooxygenase-2 expression in rat small intestine following administration of indomethacin: Relation to intestinal hypermotility. J Gastroenterol Hepatol 2005;20(1):38-45.
Church PC, Turner D, Feldman BM, et al. Systematic review with meta-analysis: Magnetic resonance enterography signs for the detection of inflammation and intestinal damage in Crohn's disease. Aliment Pharmacol Ther 2015;41:153-166.
Menys A, Puylaert C, Tutein Nolthenius CE, et al. Quantified terminal ileal motility during MR enterography as a biomarker of Crohn disease activity: Prospective multi-institution study. Radiology 2018;289(2):428-435.
Menys A, Taylor SA, Emmanuel A, et al. Global small bowel motility: Assessment with dynamic MR imaging. Radiology 2013;269(2):443-450.
Plumb AA, Menys A, Russo E, et al. Magnetic resonance imaging-quantified small bowel motility is a sensitive marker of response to medical therapy in Crohn's disease. Aliment Pharmacol Ther 2015;42(3):343-355.
Camilleri M, Madsen K, Spiller R, Greenwood-Van Meerveld B, Verne GN. Intestinal barrier function in health and gastrointestinal disease. Neurogastroenterol Motil 2012;24(6):503-512.
Kubica P, Kot-Wasik A, Wasik A, Namiesnik J, Landowski P. Modern approach for determination of lactulose, mannitol and sucrose in human urine using HPLC-MS/MS for the studies of intestinal and upper digestive tract permeability. J Chromatogr B Analyt Technol Biomed Life Sci 2012;907:34-40.
Cronin CG, Delappe E, Lohan DG, Roche C, Murphy JM. Normal small bowel wall characteristics on MR enterography. Eur J Radiol 2010;75:207-211.
Hordonneau C, Buisson A, Scanzi J, et al. Diffusion-weighted magnetic resonance imaging in ileocolonic Crohn's disease: Validation of quantitative index of activity. Am J Gastroenterol 2014;109:89-98.
Buisson A, Joubert A, Montoriol PF, et al. Diffusion-weighted magnetic resonance imaging for detecting and assessing ileal inflammation in Crohn's disease. Aliment Pharmacol Ther 2013;37(5):537-545.
Bland JM, Altman DG. Statistical methods for assessing agreement between two methods of clinical measurement. Lancet 1986;1(8476):307-310.
Barnhart HX, Barboriak DP. Applications of the repeatability of quantitative imaging biomarkers: A review of statistical analysis of repeat data sets. Transl Oncol 2009;2(4):231-235.
Administration TUSFaD. FDA Drug Safety Communication: FDA evaluating the risk of brain deposits with repeated use of gadolinium-based contrast agents for magnetic resonance imaging (MRI). In: FDA, editor. 2015.
Bjarnason I, Scarpignato C, Holmgren E, Olszewski M, Rainsford KD, Lanas A. Mechanisms of damage to the gastrointestinal tract from nonsteroidal anti-inflammatory drugs. Gastroenterology 2018;154(3):500-514.
Hawkey CJ, Ell C, Simon B, et al. Less small-bowel injury with lumiracoxib compared with naproxen plus omeprazole. Clin Gastroenterol Hepatol 2008;6(5):536-544.
Barth M, Breuer F, Koopmans PJ, Norris DG, Poser BA. Simultaneous multislice (SMS) imaging techniques. Magn Reson Med 2016;75(1):63-81.
Grover M, Camilleri M, Hines J, et al. (13) C mannitol as a novel biomarker for measurement of intestinal permeability. Neurogastroenterol Motil 2016;28(7):1114-1119.